Key Takeaways
- Demand shock from policy, not demand destruction: US tariffs (50%) and a domestic GST rate split on Mint froze customer orders as buyers depleted inventory and reformulated blends; management calls the hit transient and expects demand back around Q4.
- Mint, the 70% revenue engine, stalled: The entire Mint portfolio, which was 70% of FY25 revenue, saw realization pressure and volume deferrals, driving the gross margin erosion this quarter.
- The answer is a faster pivot to specialties: Value-added products originally slated for FY27–FY28 are being fast-tracked, and Phase-II of the Dahej plant, housing India's largest Cooling Agent unit, commissions November 30.
- Balance sheet reset complete: ₹140 crores of IPO proceeds repaid debt, pulling net debt-to-equity from 0.8x to 0.3x, just as the capex cycle peaks.
- What to watch next quarter: Whether Phase-II commissioning hits the November 30 deadline, the pace of Cooling Agent customer conversion, and any signal that tariff or GST uncertainty is resolving to validate the Q4 demand recovery call.
The Twin Policy Shocks
- US tariff freeze: A 50% tariff announced late August led large-scale customers to accept pass-through in principle but slash orders in practice, running down in-house stock instead. One specific customer still faces ~19% tariffs even after mitigation attempts through Thailand, Ireland and other geographies.
- GST-driven reformulation: The September 2 GST Council move split Natural Menthol to 5% and Synthetic Menthol to 18% from a uniform 12%, forcing customers to rework blend compositions. The entire Mint portfolio, 70% of FY25 revenue, felt the impact as buyers paused to reassess.
- Recovery contingent on policy reversal: Management sees pent-up demand returning around Q4, but only if tariff situations are corrected as current reports suggest. Customers are described as in a bare minimum, all-out position.
Yash Parekh: "everyone is hopeful that these tariff situations will be corrected like these reports currently suggest. So, we do see this demand regardless to come back about Q4."
Margin Mechanics
- Gross margin hit from Mint realizations: Gross margin erosion was driven primarily by realization pressure in Menthol and the Mint business, with a smaller contribution from raw material cost pressure. Costing also increased due to GST-related formulation changes at the customer end.
- Menthol prices down ~10% YoY: The company plans to forward-integrate Menthol into Cooling Agents, doing less direct Menthol manufacturing and moving more downstream, a structural shift in product mix.
- Expense and depreciation drag: Higher other expenses and inventory adjustments weighed on profitability, while depreciation rose to ~₹4.8 crores in H1 FY26 from ~₹3.5 crores in H1 FY25 as major assets at Krystal Ingredients were capitalized.
- Raw material pass-through model disrupted: Under normal conditions, a large part of raw material volatility passes to customers, but the Mint business carries an inventory holding model with a defined procurement season and replenishment cycle, which amplified the quarter's headwinds from GST and Menthol realization pressure.
- No margin guidance given: Management declined to provide margin guidance, citing extremely volatile times, with the goal stated only as returning to long-term averages.
The Dahej Phase-II Catalyst
- Commissioning November 30: Phase-II of the new plant at Dahej, under subsidiary Krystal Ingredients, is expected to commence on that date with all approvals in place. The facility adds 10,829 metric tons of capacity.
- India's largest Cooling Agent unit: The plant houses over 500 MTPA of Cooling Agent capacity, plus dedicated lines for Phenol derivatives and Citral derivatives. Production of Cooling Agents starts November 30, with reasonable utilization expected from December's first half.
- Phenol derivatives timeline: MEHQ and Guaiacol production to start in Q4, around January/February. BHA, originally planned for FY28, has been fast-tracked to begin production in FY27.
- Krystal tax advantage permanent: Krystal Ingredients is eligible for a 15% corporate tax rate and government incentives, a benefit that continues in perpetuity.
- Utilization visibility still forming: Management is not focusing on capturing full utilization in FY26 due to macroeconomic headwinds; FY27 is expected to be a more normalized year with decent capacity utilization. Better visibility is expected toward Q4 for FY27.
Yash Parekh: "this gives us a tactical advantage because there is no one else in India who is currently offering that product. So, we feel fairly confident."
Strategic Pivot: Less Mint, More Specialties
- Value-added products fast-tracked: Specialty products originally planned for FY27 and FY28 are being accelerated to replace revenue from the Mint category, which management describes as the parts they can control.
- Cooling Agents as the bridge: Cooling Agents are downstream from Menthol, targeting confectionery and pain management segments, and open cross-selling opportunities across product verticals. Advanced-level discussions are ongoing with multiple customers.
- Phenol derivatives built on next-gen technology: The Phenol derivatives unit uses next-generation technologies that enhance efficiency, consistency and overall product quality.
- New customer revenues targeted for Q4: Revenues from new customers globally are expected to show up toward Q4 and roll into FY27.
- Long-term demand story intact: Steady growth expected in Oral Care, Personal Care, Wellness, Flavors, Fragrances and Alternative Medicine, supported by rising disposable income, premiumization and the shift toward natural and wellness-focused ingredients.
Yash Parekh: "We are trying to replace the revenue from the Mint category with the value-added products of specialty that we had planned for FY '27 and 28, we are fast-tracking them and bringing them much sooner so that these are the parts that we can control."
Balance Sheet & IPO
- IPO proceeds deployed for deleveraging: The company listed on NSE and BSE on August 26, and ₹140 crores from IPO proceeds were used for partial repayment of borrowings. Net debt-to-equity improved to 0.3x from 0.8x.
- Capex cycle funded: The IPO was undertaken to strengthen the balance sheet for partial debt repayment and to support the long-term growth plan, with major asset capitalization at Krystal Ingredients completed in H1.
What Management Declined to Disclose
- Category-wise profit margins or EBITDA for the new 10,829 MTPA capacity were declined, as was any capacity bifurcation by product category, with management citing the plant's multi-purpose nature and high fungibility.
- Category-wise topline for Cooling Agents was declined.
- Natural vs. synthetic Mint breakup was declined; management stated they offer the entire solution.
- Pricing/realization impact percentage from GST was deflected, with management offering to take the question offline.
- Whether Phenol derivatives are margin-accretive to the company average was not directly answered; management instead explained the rationale for entering the segment.
- Competitive advantage in MEHQ, BHA, Guaiacol, 4MAP versus a competitor using vapor-based technology was not addressed.
- Cooling Agent export targets or strategy for the 500 MTPA capacity were not provided.
- doTERRA's value-add as both key customer and shareholder went unanswered after a moderator interruption.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Phase-II commissioning | Dahej Phase-II operational, adding 10,829 MTPA capacity | November 30, 2025 |
| Cooling Agent production start | First batches, reasonable utilization from December first half | November 30, 2025 |
| MEHQ and Guaiacol production | Production start at Dahej | Q4 FY26 (Jan/Feb) |
| BHA production | Fast-tracked from FY28 | FY27 |
| Tariff-linked demand recovery | Pent-up demand returns, contingent on tariff correction | Around Q4 FY26 |
| GST-linked demand recovery | Pent-up demand returns as customers complete reformulation | Around Q4 FY26 |
| New customer revenues | Revenues from new global customers begin materializing | Toward Q4 FY26, rolling into FY27 |
| FY28 EBITDA target | Company-level EBITDA of ₹1,050–₹1,100 crores at 16%–18% margin | FY28 |
| Cooling Agent utilization normalization | Decent capacity utilization at Krystal | FY27 |
Key Metrics
| Metric | Q2 FY26 |
|---|---|
| Revenue from operations | ₹89.5 cr |
| H1 FY26 revenue from operations | ₹177.2 cr |
| EBITDA | ₹3 cr, margin of 3.4% |
| H1 FY26 EBITDA | ₹17.9 cr, margin of 10.1% |
| Net profit / loss | Net loss of ₹2.6 cr |
| H1 FY26 net profit | ₹5.4 cr, PAT margin of 3.1% |
| Cash PAT | ₹0.5 cr |
| H1 FY26 cash PAT | ₹10.3 cr |
| Depreciation (H1 FY26) | ₹4.8 cr, up from ₹3.5 cr in H1 FY25 |
| Net debt to equity | 0.3x, improved from 0.8x |
| Debt repaid | ₹140 cr: ₹97.4 cr long-term (Krystal) and ₹42.6 cr working capital (GEM Aromatics) |
| Existing plant capacity utilization | 60% |
| Menthol realizations | ~10% decline YoY in gross value |
| Mint portfolio share of revenue | ~70% as of FY25 |
| FY28 company-level revenue target | ₹1,050–₹1,100 cr at 16%–18% EBITDA margin |